EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut Microbiota in NSAID Enteropathy: Current Evidence and Future Perspectives for Therapeutic Strategies

Stefania Piccirelli, Brigida Barberio iD, Enrico Tettoni, Carla Treppiccione, Edoardo Pezzuto iD, Elisa Tabbone, Daniele Salvi iD, Luisa Bertin iD, Viviana Gerardi, Paola Cesaro, Edoardo Vincenzo Savarino iD

Pharmaceuticals · 07.07.2026 · 19 (7) · 1045

DOI: 10.3390/ph19071045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 07.07.2026. Verfasst von Stefania Piccirelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, Fondazione Poliambulanza Istituto Ospedaliero, 25124 Brescia, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed worldwide for their analgesic, antipyretic, and anti-inflammatory properties. However, their long-term use is associated with substantial gastrointestinal (GI) toxicity. Although upper GI injury has traditionally received greater attention, NSAID-induced enteropathy is now increasingly recognized as a common yet underdiagnosed condition. Advances in small-bowel imaging, particularly capsule endoscopy, have demonstrated that mucosal injury of the small intestine occurs in up to 70–80% of chronic NSAID users and may also develop after short-term exposure in otherwise healthy individuals, often without overt clinical symptoms. When symptoms do occur, NSAID-induced enteropathy is characterized by non-specific clinical manifestations and may lead to severe complications in approximately 1% of cases. The pathogenesis of NSAID-induced enteropathy is multifactorial and more complex than that underlying upper GI damage. It involves prostaglandin depletion, increased intestinal permeability, bile acid-mediated toxicity, enterohepatic recirculation of NSAIDs, and, importantly, interactions with the gut microbiota. Concomitant therapies, particularly proton pump inhibitors, may further aggravate small-bowel injury by promoting intestinal dysbiosis. Growing evidence supports a relevant contributory role for the gut microbiota as both a mediator and a modulator of NSAID-induced toxicity, affecting epithelial barrier function, oxidative stress, immune responses, and bile acid metabolism. This review provides an overview of current knowledge of NSAID-induced enteropathy, with a particular emphasis on the microbiota-driven mechanisms underlying mucosal injury. By integrating emerging microbiota-targeted therapeutic approaches, we propose a management algorithm that may help modify disease progression in a condition that remains frequently overlooked in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

NSAIDs toxicityenteropathygut microbiotamicrobial modulationsmall bowel disorderstherapeutic algorithm

Autor:innen und Institutionen

  • Department of Gastroenterology and Endoscopy, Fondazione Poliambulanza Istituto Ospedaliero, 25124 Brescia, Italy.
  • Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova-Azienda Ospedaliera di Padova, 35128 Padova, Italy.
  • Department of Translational Medicine and Surgery, Cattolica del Sacro Cuore University, 00168 Rome, Italy.
  • Gastroenterology Unit, Department of Surgery, Oncology, and Gastroenterology, University of Padova, 35128 Padova, Italy.

ORCID-Profile: Brigida Barberio, Edoardo Pezzuto, Daniele Salvi, Luisa Bertin, Edoardo Vincenzo Savarino

Zitieren

APA

Piccirelli, S., Barberio, B., Tettoni, E., Treppiccione, C., Pezzuto, E., Tabbone, E., Salvi, D., Bertin, L., Gerardi, V., Cesaro, P., & Savarino, E. V. (2026). Gut Microbiota in NSAID Enteropathy: Current Evidence and Future Perspectives for Therapeutic Strategies. Pharmaceuticals, 19(7), 1045. https://doi.org/10.3390/ph19071045

Vancouver

Piccirelli S, Barberio B, Tettoni E, Treppiccione C, Pezzuto E, Tabbone E, et al. Gut Microbiota in NSAID Enteropathy: Current Evidence and Future Perspectives for Therapeutic Strategies. Pharmaceuticals. 2026;19(7):1045. doi:10.3390/ph19071045

BibTeX
@article{Piccirelli2026,
  author = {Piccirelli, Stefania and Barberio, Brigida and Tettoni, Enrico and Treppiccione, Carla and Pezzuto, Edoardo and Tabbone, Elisa and Salvi, Daniele and Bertin, Luisa and Gerardi, Viviana and Cesaro, Paola and Savarino, Edoardo Vincenzo},
  title = {Gut Microbiota in NSAID Enteropathy: Current Evidence and Future Perspectives for Therapeutic Strategies},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1045},
  doi = {10.3390/ph19071045}
}
Kostenlos starten →